Atypical Presentations of Alzheimer Disease

Alzheimer disease (AD) is most commonly associated with an amnestic phenotype in which progressive episodic memory loss is the predominant early feature. However, a significant minority of patients — particularly those with early-onset AD (before age 65) — present with predominantly nonmemory cognitive deficits. These atypical AD variants include posterior cortical atrophy (PCA), logopenic variant primary progressive aphasia (lvPPA), dysexecutive AD, and behavioral variant AD. Each variant targets distinct functional brain networks while sharing the common underlying molecular pathology of amyloid-beta (Aβ) plaques and neurofibrillary tau tangles. Recognition of these phenotypes is essential because delays in diagnosis are common, biomarker confirmation is critical, and emerging disease-modifying therapies require accurate pathologic classification.

Overview of Atypical AD Variants

Atypical AD variants are defined by predominant impairment in nonmemory cognitive domains at onset and early in the disease course. These variants represent the extremes of a common underlying functional spectrum of neurodegeneration, with each phenotype reflecting selective vulnerability of specific large-scale brain networks. Neuroimaging techniques — particularly FDG-PET and tau PET — reveal distinct regional abnormalities for each variant, whereas amyloid PET shows a more diffuse and overlapping distribution that is less tightly coupled to clinical phenotype.

Posterior Cortical Atrophy

Posterior cortical atrophy (PCA), originally described by Benson and colleagues in 1988, is characterized by progressive higher-order visual dysfunction with relative preservation of memory, language, executive function, behavior, and personality early in the disease course. AD is the most common underlying pathology (~80%), though PCA can also result from Lewy body disease, corticobasal degeneration, and prion disease.

Clinical Features

Patients with PCA typically present between ages 50 and 64, though late-onset cases (≥65 years) occur in up to 15% of patients. Initial symptoms are often attributed to ocular disease, leading to multiple eye examinations and prescriptions for corrective lenses before the true diagnosis is recognized.

Core Features and Syndromes

The 2017 consensus criteria (Crutch et al.) require at least 3 of 16 core cognitive features present as early or presenting signs. These features span two major visual processing pathways:

Classification Framework

• PCA-pure: Meets PCA criteria without other associated syndromes
• PCA-plus: Meets PCA criteria and additionally meets criteria for another syndrome (e.g., corticobasal syndrome, dementia with Lewy bodies)
• PCA-AD: PCA with confirmed AD biomarkers (CSF or amyloid PET); definite PCA-AD requires autopsy confirmation

Evaluation and Imaging

Computerized threshold visual field testing (Humphrey fields) is recommended when PCA is suspected, as homonymous defects are detected in up to 62% of patients. FDG-PET can reveal significant occipitoparietal hypometabolism even when structural MRI appears normal. The cingulate island sign (occipital hypometabolism with relative sparing of posterior cingulate metabolism) is a feature of PCA, including in the absence of Lewy body copathology.

Prognosis

Nearly all patients meeting 2017 PCA criteria progress to dementia over time. Posterior functions deteriorate faster than initially spared domains, but paradoxically, global cognitive measures (e.g., MMSE) may decline more slowly than in typical AD. Median survival is approximately 8–10 years from symptom onset.

Logopenic Variant Primary Progressive Aphasia

Logopenic variant PPA (lvPPA) is characterized by impaired word retrieval leading to reduced speech fluency, with relative preservation of grammar and single-word comprehension. Of the three PPA subtypes, lvPPA has the strongest association with AD neuropathologic change, occurring in approximately 70% of cases.

PPA Subtypes Comparison

Risk Factors and Progression

Unlike amnestic AD, APOE ε4 is not a reliable risk factor for PPA, including the logopenic variant. A history of learning disabilities in the affected individual or first-degree family members has been demonstrated at higher frequency in PPA compared to other dementias and controls, suggesting a predisposition for vulnerability of the language network. PPA with elevated amyloid biomarkers tends to show more widespread and bilateral atrophy with earlier contralateral hemisphere involvement and greater functional decline than amyloid-negative PPA.

Dysexecutive Alzheimer Disease

Dysexecutive AD is characterized by predominant impairment in executive functions — specifically working memory, cognitive flexibility, and inhibition — with onset typically between ages 45 and 70. These patients are often still in the workforce and have parental responsibilities, making early recognition particularly consequential.

Clinical Features

The hallmark of dysexecutive AD is a striking disconnect between cognitively effortful tasks (markedly impaired) and well-learned automatic behaviors (relatively preserved). Patients struggle with multitasking, learning new software, sequential tasks (e.g., making a sandwich, assembling furniture), and mental number manipulation, while seemingly more complex but familiar activities (e.g., driving) are preserved. These difficulties are frequently misattributed to “forgetting,” leading patients and families to focus on memory rather than recognizing executive dysfunction as the primary deficit.

Proposed Diagnostic Criteria

Recently proposed criteria for progressive dysexecutive syndrome stipulate that the behavioral variant FTD syndrome is exclusionary. Three diagnostic levels have been defined:

• Progressive dysexecutive syndrome: Persistent, predominant, progressive decline ≥6 months in core executive functions (working memory, cognitive flexibility, or inhibition) without predominant behavioral features
• Possible dysexecutive AD: Meets clinical criteria plus evidence of AD pathophysiology (decreased CSF Aβ42 or Aβ42/Aβ40 ratio; or abnormal amyloid PET)
• Definite dysexecutive AD: Meets possible criteria plus elevated CSF pTau, abnormal tau PET, autosomal dominant AD genetic variant, or postmortem confirmation of AD pathology

Behavioral Variant Alzheimer Disease

Behavioral variant AD is characterized by prominent changes in personality, social behavior, emotional responsiveness, and motivation — clinically resembling behavioral variant frontotemporal dementia (bvFTD) but caused by underlying AD pathology. Distinction from bvFTD requires biomarker confirmation.

Clinicopathologic Comparison

Corticobasal Syndrome Due to AD

Corticobasal syndrome (CBS) is a clinical phenotype characterized by asymmetric parkinsonism, limb apraxia, dystonia, myoclonus, and cortical sensory loss. Although traditionally associated with corticobasal degeneration (CBD), AD pathology accounts for a significant minority of CBS cases. When CBS is caused by AD, patients have positive amyloid and tau biomarkers. The overlap between PCA-plus and CBS due to AD underscores the importance of biomarker testing in patients with asymmetric cortical syndromes.

Early-Onset Alzheimer Disease

Early-onset AD (EOAD), defined as onset before age 65, accounts for approximately 5–10% of all AD cases and is disproportionately associated with atypical phenotypes. In some EOAD cohorts, nonmemory presentations may outnumber the classic amnestic phenotype.

Diagnostic Approach

Diagnosing atypical AD requires a systematic, multimodal approach that integrates clinical assessment, neuropsychological testing, neuroimaging, and biomarker analysis. Because clinical phenotype alone cannot reliably predict underlying pathology, biomarker confirmation is indispensable.

Step-by-Step Evaluation

Neuroimaging Patterns by Variant

Differential Diagnosis by Variant

Management Principles

Management of atypical AD variants combines pharmacologic and individualized nonpharmacologic strategies. Care must be tailored to the specific cognitive domain affected and to the unique psychosocial challenges of what is often a younger-onset dementia.

Pharmacotherapy

• Cholinesterase inhibitors and NMDA receptor antagonists: Commonly used and recommended for atypical AD, though efficacy for executive, visual, or language features has not been specifically evaluated in these phenotypes
• Anti-amyloid monoclonal antibodies: Appropriate use recommendations state that absence of data in atypical AD is not a contraindication, but this limitation should be acknowledged in shared decision-making; patients with very high tau levels (common in dysexecutive AD) may have attenuated benefit
• Symptomatic medications: Antidepressants, anxiolytics, or antipsychotics for secondary psychiatric symptoms, with vigilance against overmedication
• PCA-specific: If visual hallucinations, parkinsonism, or REM sleep behavior disorder emerge, evaluate for Lewy body copathology and manage accordingly

Nonpharmacologic Strategies

• Dysexecutive AD: Simplify environments, avoid multitasking, use checklists, capitalize on well-learned routines, address the role of anxiety in executive performance
• Behavioral variant AD: Behavioral redirection and distraction, structured routines, environmental modifications, care partner training
• PCA: Visual rehabilitation strategies, occupational therapy for activities of daily living, driving cessation counseling
• Logopenic PPA: Speech-language pathology (emerging evidence for efficacy from the Communication Bridge-2 trial); strategies addressing communication breakdowns between patients and care partners
• All variants: Care partner education, genetic counseling, social work support for disability and employment issues, referral to clinical trials, and connection to support organizations

Health Equity Considerations

Because atypical AD variants often have a younger age of onset, the diagnostic journey frequently requires years and visits to multiple clinicians. This places extraordinary demands on persistence, financial resources, and health literacy, widening access-to-care gaps for individuals from underrepresented backgrounds. AD disproportionately affects non-Hispanic Black (up to 2× risk) and Hispanic (up to 1.5× risk) older adults, yet these populations remain significantly underrepresented in research cohorts. Collaborative efforts from multisite studies, Alzheimer’s Disease Research Centers, and patient advocacy organizations are actively working to address these disparities.

References

1. Jones D, Pelak V, Rogalski E. Atypical presentations of Alzheimer disease. Continuum (Minneap Minn). 2024;30(6):1614-1641.
2. Crutch SJ, Schott JM, Rabinovici GD, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017;13(8):870-884.
3. Townley RA, Graff-Radford J, Mantyh WG, et al. Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes. Brain Commun. 2020;2(1):fcaa068.
4. Graff-Radford J, Yong KXX, Apostolova LG, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol. 2021;20(3):222-234.
5. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014.
6. Ossenkoppele R, Pijnenburg YAL, Perry DC, et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain. 2015;138(Pt 9):2732-2749.
7. Corriveau-Lecavalier N, Barnard LR, Bhota H, et al. Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases. Brain. 2024;147(4):1483-1496.
8. Mesulam MM, Rogalski EJ, Wieneke C, et al. Primary progressive aphasia and the evolving neurology of the language network. Nat Rev Neurol. 2014;10(10):554-569.
9. Conca F, Esposito V, Giusto G, Cappa SF, Catricala E. Characterization of the logopenic variant of primary progressive aphasia: a systematic review and meta-analysis. Ageing Res Rev. 2022;82:101760.
10. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263-269.